Effects of different doses of rosuvastatin on blood lipids and lipoproteins, endothelial function, and cerebral blood flow in patients with hyperlipidemia and cerebral ischemic stroke-complicated hypertension
- Authors: Bubnova M.G1, Semenova E.G2, Aronov D.M1, Batysheva T.T3
-
Affiliations:
- State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
- Branch Six, Moscow Research-and-Practical Center for Medical Rehabilitation, Regenerative and Sport Medicine, Moscow Healthcare Departmen
- Research-and-Practical Center for Pediatric Psychoneurology, Moscow Healthcare Department
- Issue: Vol 4, No 2 (2013)
- Pages: 72-80
- Section: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45048
- DOI: https://doi.org/10.26442/CS45048
- ID: 45048
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M. G Bubnova
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscow
Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ Минздрава РФ
E. G Semenova
Branch Six, Moscow Research-and-Practical Center for Medical Rehabilitation, Regenerative and Sport Medicine, Moscow Healthcare Departmenврач ГБУЗ МНПЦ МРВСМ филиал №6 ДЗ г. Москвы
D. M Aronov
State Research Center for Preventive Medicine, Ministry of Health of the Russian Federation, Moscowд-р мед. наук, проф., засл. деят. науки РФ, рук. лаб. кардиологической реабилитации ФГБУ ГНИЦ ПМ Минздрава РФ
T. T Batysheva
Research-and-Practical Center for Pediatric Psychoneurology, Moscow Healthcare Departmentд-р мед. наук, проф., дир. ГКУЗ НПЦ ДП ДЗ г. Москвы
References
- Petersen S, Peto V, Rayner M et al. European cardiovascular disease statistics. London: British Heart Foundation 2005; p. 100.
- Константинов В.О. Эволюция статиновой терапии: продолжение следует. Сердце. 2004; 4: 199–204.
- Карпов Ю.А., Сорокин Е.В. Интенсивное медикаментозное лечение больных с атеросклерозом. Кардиология. 2005; 8: 4–7.
- Камчатнов П.Р., Чугунов А.В., Воловец С.А., Кузин В.М. Вторичная профилактика ишемического инсульта. Актуальные вопр. болезней сердца и сосудов. 2010; 4: 45–9.
- Дамулин И.В. Принципы реабилитации пациентов, перенесших инсульт. Справ. практ. врача. 2003; 3 (2): 21–4.
- The PROGRESS Collaboratory Group. Randomised trial of a perindopril - based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
- Amarenco P, Bogousslavsky S, Callahan A et al. High - dose Atorvastatin after stroke or transient ischemic attack. New Engl J Med 2006; 355: 549–59.
- Furie K.L., Kasner S.E., Adams R.J. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for Healthcare Professionals From Heart Association/American Stroke Association. Stroke 2011; 42: 227–76.
- Mullard A.J., Reeves M.J., Jacobs B.S. et al. Lipid testing and lipid - lowering therapy in hospitalized ischemic stroke and transient ischemic attack patients: results from a statewide stroke registry. Stroke 2006; 37: 44–9.
- Zacco A, Togo J, Spence K et al. 3 - hydroxy - 3 - methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003; 23: 11104–11.
- Ovbiagele B, Kidwell C.S., Saver J.L. Expanding indications for statins in cerebral ischemia: a quantitative study. Arch Neurol 2005; 62: 67–72.
- Mancia G, Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the of the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 26: 1105–87.
- American Heart Association. AHA dietary guidelines: revision 2000. Circulation 2000; 102: 2284–99.
- Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 4: 237–46.
- Голиков П.П., Николаева Н.Ю., Гавриленко И.А. и др. Оксид азота и перекисное окисление липидов как факторы эндогенной интоксикации при неотложных состояниях. Патол. физиология и эксперим. терапия. 2000; 2: 6–9.
- Moshage H, Kok B, Huizenga J.R., Jansen P.L. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41 (6 Pt. 1): 892–6.
- White C.M. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963–70.
- Olsson A.G., Mc Taggart F, Raza A. Rosuvastatin a highly effective new HMG - CoA - reducuctase inhibitor. Cardiovasc Drug Rev 2002; 20: 303–28.
- Olsson A.G. Rosuvastatin in dyslipidemia and coronary heart disease. Science Press. Current Med Group Ltd 2004; p. 41–2.
- Nicholls S.J., Brandrup-Wognsen G, Palmer M, Barter P.J. Meta - analysis of comparative efficacy of increasing dose of atorvastatin vs rosuvastatin vs simvastatin on lowering levels of atherogenic lipids from VOYAGER. Am J Cardiol 2010; 105: 69–76.
- Mc Kenney J.M., Jones P.H., Adamczyk M.A. et al. Comparison of efficacy of rosuvastatin vs atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689–98.
- Hunninghake D.B., Stein E.A., Bays H.E. et al. Rosuvastatin improves the atherogenic and artheroprotective lipid profile in patients with hypertriglyceridaemia. Coron Artery Dis 2004; 15: 115–23.
- Tirschwell D.L., Smith N.L., Heckbert S.R. et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63: 1868–75.
- Anzej S, Bozic M, Antovic A et al. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res 2007; 120: 39–46.
- Laufs U, Gertz K, Dirnagl U et al. Rosuvastatin, a new-CoA-reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res 2002; 942: 23–30.
- Rikitake Y, Kawashima S, Takeshita S et al. Anti - oxidative properties of fluvastatin, an HMG - CoA - reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol - fed rabbits. Atheroscler 2001; 154: 87–96.
- Fournier A, Messerli F.H., Achard J.M., Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43 (8): 1343–7.
- Гомазков О.А. Эндотелин в кардиологии: молекулярные, физиологические и патологические аспекты. Кардиология. 2001; 2: 50–8.
- Лелюк В.Г., Лелюк С.Э. Ультразвуковая ангиология. М.: Реальное время, 2003.
- Crouse J.R., Raichlen J.S., Evans G.W. et al. Effects of Rosuvastatin on progression of carotid intima–media thickness in low - risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344–53.
- White C.M. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963–70.
- Cheng W.M. Rosuvastatin in the management of hyperlipidemia. Clin Therapeut 2004; 26: 1368–87.